The antiviral pill manufactured by Merck, “could really represent a point of turning point in the fight to Covid“and” when administered in the first stage of the disease could reduce hospitalization“, he claims Giovanni Maga, director of the Institute of Molecular Genetics of the Cnr of Pavia, at the breaking latest news agency. “It is an antiviral in the strict sense, unlike the other three drugs recently approved by Aifa that regulate the anti-inflammatory response”, explains Maga, according to which “at the moment the safety profile is very good”